Business Wire

Anomali Appoints Justin Coker as Vice President and General Manager of EMEA to Drive Growth Across Europe and the Middle East

Share

Anomali, the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that multi-decade industry veteran Justin Coker has been named Vice President and General Manager of Europe and the Middle East (EMEA). Coker takes the region’s helm during a period of explosive demand for Anomali’s leading cybersecurity solutions, which are delivering unmatched ability in precision threat detection and comprehensive response that stops immediate and future breaches and attacks.

“Anomali is building a world-class leadership team as we continue on our phenomenal growth trajectory around the world. Justin brings a powerful combination of experience and skill to ensure that our public and private sector customers and partners receive the attention needed to build efficient, high-performance security infrastructures that stop advanced breaches and the attackers targeting their enterprises,” said Ahmed Rubaie, CEO, Anomali. “We are excited to welcome Justin to the company; his commitment to the organization and regional expertise makes him the perfect leader for the job.”

Coker has spent more than 20 years in senior sales management roles at leading enterprise cybersecurity companies. He joins Anomali from IronNet Cybersecurity, where, as VP of EMEA, he built out a sales team from the ground up on its journey to its recent IPO. Prior to then, he was VP of EMEA at Skybox Security, where he grew the business from a start-up to a team of 50, along the way winning a comprehensive list of EMEA's largest organizations as customers and creating strong alliances with many of the premier partner organizations across the region. Before that, while at Symantec, he led the United Kingdom’s and Ireland's retail banking and finance enterprise sales team for five years. He has held other successful IT sales positions at AXENT Technologies, Parametric Technology, and Fujitsu. Throughout his professional career, Coker has exceeded expectations at building and scaling successful sales teams and has remained enthusiastic about delivering business value to his clients and partners.

“I am excited to be joining Anomali at such a pivotal phase of growth and innovation. I look forward to driving our deeper portfolio adoption across EMEA through the development of existing and new markets, coupled with the continued expansion of our global channel and technology partner ecosystem,” said Coker. “Anomali’s go-to-market approach in EMEA is centered around our continued passion for creating strong partnerships with our global enterprise clients and helping them capitalize upon significant business value. I look forward to fulfilling our mission to strengthen customers’ security efficacy and efficiency, fueled by our intelligence-driven detection and response solutions and world-class customer-focused team.”

Coker and his team will be furthering access to the award-winning Anomali portfolio, which includes ThreatStream, our leading threat management platform, Lens, the industry’s only Natural Language Processing (NLP) product that identifies all threats and IOCs in any web content to operationalize them across security infrastructures, and Match, our advanced global attacker detection and response solution that quickly identifies and responds to threats in real-time by automatically correlating all security telemetry data against active threat intelligence.

Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
Detect LIVE Conference: https://www.anomali.com/detect-live

About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management and refined by artificial intelligence and machine learning, the Anomali platform delivers proprietary capabilities that correlate an extraordinary volume of telemetry from customer-deployed security solutions with the largest repository of global intelligence, empowering security operations teams to detect threats with precision, optimize response, achieve resiliency, and stop attackers and breaches. Our Cloud-first SaaS-based solutions easily integrate into existing security tech stacks and accommodate hybrid deployments. Founded in 2013, Anomali serves public and private sector organizations, ISACs, MSSPs, and Global 1000 customers worldwide in every major industry. Leading venture firms including Google Ventures, General Catalyst, and IVP back Anomali. Learn more at www.anomali.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Joe Franscella
news@anomali.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 06:00:00 EET | Press release

The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow

DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 05:00:00 EET | Press release

DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem. The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release

LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa

VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release

VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 01:00:00 EET | Press release

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye